Description
Global Workshop on Access to Rare Disease Diagnosis and Treatment | Rare Disease Day 2023
Reimbursement of drugs from pharmaceutical companies today occurs
on a per-unit basis, which spreads out the costs of drugs for chronic conditions over
years. However, the cost of a cell or gene therapy would be much complicated as it
is potentially in a single payment with the unknown of benefits and risks in a long
term. This presentation will explore the payment challenges for payers and healthcare
providers (such as Medicare, Medicaid, BlueCross/BlueShield, etc.) as well as
several alternative payment mechanisms.